Bonima has a single manufacturing facility in El Salvador, Central America which produces the entire line of MK products. Since 1963, Bonima has commercialized “MK PHARMACEUTICALS” for markets in the Central American region, Panama, Dominican Republic, Haiti, Belize, Bahamas, Grand Cayman, Jamaica, Trinidad and Tobago, and Barbados through a network of subsidiaries, distributors and representatives. In August 1995, MK Pharmaceuticals became part of the Bayer Groups in Central America and the Caribbean. All MK products comply with Good Marketing Practices (GMP) and meet as well as exceed the highest International Quality Standards. MK Pharmaceuticals are manufactured using the latest European technology and equipment approved and monitored by Bayer AG in Germany. Bonima is engaged in research and development of the MK formulations and dosage forms with improved efficacy and safety levels.